{"schema_version":"secwatch.filing_event.v1","accession":"0001425450-23-000098","form_type":"8-K","ticker":"KIDS","cik":"0001425450","company_name":"ORTHOPEDIATRICS CORP","filed_at":"2023-07-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.891024+00:00","generated_at":"2026-06-12T21:54:51.138331+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"OrthoPediatrics Q2 revenue $39.6M (+20% YoY); net loss $2.9M, FY guide reaffirmed","bullets":["Total revenue $39.6M, +20% vs $32.9M in Q2 2022; US +19%, international +25%.","Trauma & Deformity revenue $27.5M (+22%), Scoliosis $10.9M (+16%), Sports Med/Other $1.2M (+23%).","Gross margin 76% (flat YoY); operating expenses $35.6M (+24%).","Net loss $2.9M ($0.13 loss per share) vs $0.3M loss a year ago; adj. EBITDA $2.3M vs $2.1M.","FY 2023 revenue guidance reiterated at $148M–$151M (21–23% growth); adj. EBITDA expected $3M–$4M."],"urls":{"canonical":"https://secwatch.observer/filing/0001425450-23-000098","json":"https://secwatch.observer/filing/0001425450-23-000098.json","markdown":"https://secwatch.observer/filing/0001425450-23-000098.md","text":"https://secwatch.observer/filing/0001425450-23-000098.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1425450/000142545023000098/0001425450-23-000098-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1425450/000142545023000098/kids-20230731.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T21:54:51.138331+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2c4369ab8db174c09c3a8b98976c40c875cf7678","claim":"ORTHOPEDIATRICS CORP reported the second quarter ended June 30, 2023 results: revenue $39.6 million, net income $2.9 million, EPS $0.13 per basic and diluted share. Guidance reaffirmed.","evidence_excerpt":"OrthoPediatrics Corp. Reports Second Quarter 2023 Financial Results Record Setting Quarterly Revenue of $39.6 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1425450/000142545023000098/0001425450-23-000098-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Revenue","value":"$39.6 million"},{"label":"Net income","value":"$2.9 million"},{"label":"EPS","value":"$0.13 per basic and diluted share"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}